SCHEMBL18486308

SCHEMBL18486308

[CH2]CCC(OC(c1ccccc1)(c1ccc(OC)cc1)c1ccc(OC)cc1)C(C(=O)O)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 8/20 0.49
SLC6A1 P30531 2/20 0.40
SLC6A11 P48066 1/20 0.40
GAA P10253 1/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
LDHA P00338 1/20 0.38
CNR2 P34972 1/20 0.38
ALDH1A1 P00352 2/20 0.38
KCNH2 Q12809 1/20 0.37
PLAU P00749 1/20 0.37
ELANE P08246 1/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7048548 0.72 KIF11 (0.48) KIF11SLC6A1SLC6A11PPARGPPARA
SCHEMBL17928455 0.70 KIF11 (0.46) KIF11SLC6A1SLC6A11ALDH1A1KCNH2
SCHEMBL28346610 0.70 KIF11 (0.44) KIF11ALDH1A1KCNH2KMT2A
SCHEMBL7008086 0.70 KMT2A (0.43) KIF11ALDH1A1KCNH2CYP3A4CYP2D6
SCHEMBL21562153 0.70 CA4 (0.46) KIF11ALDH1A1KCNH2NPC1RAB9A
SCHEMBL17173364 0.70 CA4 (0.46) KIF11ALDH1A1KCNH2NPC1RAB9A
SCHEMBL8454432 0.70 KIF11 (0.45) KIF11CNR2KCNH2KMT2A
SCHEMBL20371123 0.69 KIF11 (0.51) KIF11KCNH2CYP2C9SMN1; SMN2
SCHEMBL25713808 0.69 KIF11 (0.51) KIF11SLC6A1SLC6A11GAAPPARG
SCHEMBL2985182 0.69 KIF11 (0.49) KIF11SLC6A1SLC6A11KCNH2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3130597-B1 OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL KYOWA KIRIN CO LTD (JP) 2021-11-10 EP disclosed
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-07-09 US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 US disclosed
EP-3130597-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF Kyowa Hakko Kirin Co., Ltd. (JP) 2017-02-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof RNGTT, UPF1, NSUN3 KIF11 3637/4885SLC6A1 4581/4885SLC6A11 4665/4885
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF RNGTT, UPF1, NSUN3 KIF11 3585/4885SLC6A1 4584/4885SLC6A11 4665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.